In our study, the CR rate at the end of the induction period (50.0%) was similar to those previously reported in the global phase 3 QuANTUM-First study of patients with FLT3-ITD AML receiving either quizartinib plus chemotherapy (54.9% CR) or placebo plus chemotherapy (55.4% CR) [20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.